Drugs Landscape 2017 Propecia

Drugs Landscape, 2017 Propecia -Global API Manufacturers, Marketed and Drug Insights

The study of Global Propecia Market 2017 industry is very important to enhance business productivity and for the study of market forecast. This New Report presented by Orbis Reseach contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.


Propecia Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location.

The report covers the Global Market Assessment of the Propecia covering the historical global sales and also provides the Propecia sales estimation during the forecasted period (2017-2019).

The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.

Propecia results

In addition to this, the report also provides the SWOT analysis for Propecia and emerging therapies in this space.


A review of the Propecia, based on information derived from company and industry-specific sources

Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification

Coverage of the Drug Master Files and API Manufacturers by country

Patent Expiry Timeline and Exclusivity Details

Route of Synthesis of the API

Forecasted Sales Figure from 2017-2019

Market competition and emerging therapies

SWOT Analysis

Report Introduction
Propecia- Overview
Product Description
Route of Synthesis
Mechanism of Action
Adverse Reactions
Regulatory Milestones by Region
Deals and Partnerships
Product Details
Propecia Sales Assessment
Historical Sales
Forecasted Sales
Patent Details by Region
Company Financials
Market Competition
Emerging Therapies*
Drug 1
Product Description
Research and Development
Product Development Activities
SWOT Analysis
Consulting Services
Contact Us

About Us:

Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.


Hair growth drugs may cause erectile dysfunction

There is a higher risk of persistent erectile dysfunction (ED) among men who use drugs to treat hair loss, a research has said.

Erectile dysfunction is the inability to get or maintain an erection firm enough to have sexual intercourse.

The research revealed that exposure to hair growth drugs, which have finasteride or dutasteride as active ingredients, have greater chances of causing ED than other risk factors like diabetes, smoking, and hypertension.

The study found that persistent erectile dysfunction continued long after discontinued usage of the drugs and the use of sex enhancement drugs.

The study was carried out by researchers from Northwestern University in the United States.

“Prior to the new study, there was no strong evidence that finasteride and dutasteride cause sexual problems that continue after men stop taking them.

“Our study shows men who take finasteride or dutasteride can get persistent erectile dysfunction, in which they will not be able to have normal erections for months or years after stopping finasteride or dutasteride,” said Steven Belknap, a research assistant professor at Northwestern University Feinberg school of medicine.

“Finasteride and dutasteride are drugs that are male hormone blockers.

These drugs block the conversion of testosterone, primary male sex hormone, to its more active form, 5 alpha dihydrotestosterone.

“Finasteride is prescribed to some men with prostate enlargement or baldness. Dutasteride is prescribed to some men with prostate enlargement.

“The association between debilitating sexual dysfunction and exposure to finasteride or dutasteride should be of particular interest to prescribers and patients considering medical management of androgenic alopecia (hair loss) or symptomatic treatment of enlarged prostate.”

The study, which was published in PeerJ, said 167 of the 11,909 men studied in the research developed persistent erectile dysfunction that continued for about 1,348 days after stopping usage of the drugs.

Men under age 42 who had more than 205 days of finasteride or dutasteride exposure had 4.9% higher risk of persistent erectile dysfunction than men with reduced exposure, the researchers found.


propecia side effects